RUBIFEN

This brand name is authorized in Spain, Lithuania, Malta, New Zealand, Singapore

Active ingredients

The drug RUBIFEN contains one active pharmaceutical ingredient (API):

1 Methylphenidate UNII 4B3SC438HI - METHYLPHENIDATE HYDROCHLORIDE

Methylphenidate HCl is a mild central nervous system (CNS) stimulant. The mode of therapeutic action in Attention Deficit Hyperactivity Disorder (ADHD) is not known. Methylphenidate is thought to block the reuptake of noradrenaline and dopamine into the presynaptic neurone and increase the release of these monoamines into the extraneuronal space. Read about Methylphenidate

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
RUBIFEN Immediate release tablet, Sustained release tablet	Medicines and Medical Devices Safety Authority (NZ)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
N06BA04	Methylphenidate	N Nervous system → N06 Psychoanaleptics → N06B Psychostimulants, agents used for ADHD and nootropics → N06BA Centrally acting sympathomimetics
Discover more medicines within N06BA04

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: ES	Centro de información online de medicamentos de la AEMPS	Identifier(s): 55369, 65152, 65153, 84352, 84353, 84354, 84355
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1087157, 1087158
Country: MT	Medicines Authority	Identifier(s): AA565/85601, AA853/00401
Country: NZ	Medicines and Medical Devices Safety Authority	Identifier(s): 10946, 10947, 11317, 9368
Country: SG	Health Sciences Authority	Identifier(s): 10743P